Literature DB >> 23924639

WHO option B+: early experience of antiretroviral therapy sequencing after cessation of breastfeeding and risk of dermatologic toxicity.

Deborah Cohan, Julia Mwesigwa, Paul Natureeba, Flavia Aliba Luwedde, Veronica Ades, Albert Plenty, Abel Kakuru, Jane Achan, Tamara Clark, Beth Osterbauer, Moses Kamya, Diane Havlir.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23924639      PMCID： PMC3738916          DOI： 10.1097/QAI.0b013e31828011ca

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN： 1525-4135            Impact factor:   3.731


× No keyword cloud information.
  15 in total

1.  Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression.

Authors:  Eugenia Negredo; Luís Cruz; Roger Paredes; Lidia Ruiz; Carmina R Fumaz; Anna Bonjoch; Silvia Gel; Albert Tuldrà; Montserrat Balagué; Susan Johnston; Albert Arnó; Antoni Jou; Cristina Tural; Guillem Sirera; Joan Romeu; Bonaventura Clotet
Journal:  Clin Infect Dis       Date:  2002-01-02       Impact factor: 9.079

2.  Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy.

Authors:  P Barreiro; V Soriano; F Blanco; C Casimiro; J J de la Cruz; J González-Lahoz
Journal:  AIDS       Date:  2000-05-05       Impact factor: 4.177

3.  A randomized controlled trial investigating the efficacy and safety of switching from a protease inhibitor to nevirapine in patients with undetectable viral load.

Authors:  J A Arranz Caso; J C López; I Santos; V Estrada; V Castilla; J Sanz; J Sanz; J P Molina; M Fernández Guerrero; M Górgolas
Journal:  HIV Med       Date:  2005-09       Impact factor: 3.180

4.  Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with hiv-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study.

Authors:  L Ruiz; E Negredo; P Domingo; R Paredes; E Francia; M Balagué; S Gel; A Bonjoch; C R Fumaz; S Johnston; J Romeu; J Lange; B Clotet
Journal:  J Acquir Immune Defic Syndr       Date:  2001-07-01       Impact factor: 3.731

5.  Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia.

Authors:  Leonardo Calza; Roberto Manfredi; Vincenzo Colangeli; Livia Tampellini; Teresa Sebastiani; Daria Pocaterra; Francesco Chiodo
Journal:  AIDS       Date:  2005-07-01       Impact factor: 4.177

6.  Efavirenz to nevirapine switch in HIV-1-infected patients with dyslipidemia: a randomized, controlled study.

Authors:  Jean-Jacques Parienti; Veronique Massari; David Rey; Patrice Poubeau; Renaud Verdon
Journal:  Clin Infect Dis       Date:  2007-06-06       Impact factor: 9.079

7.  Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine.

Authors:  Eugenia Negredo; Josep Ribalta; Roger Paredes; Raimón Ferré; Guillem Sirera; Lidia Ruiz; Juliana Salazar; Peter Reiss; Lluís Masana; Bonaventura Clotet
Journal:  AIDS       Date:  2002-07-05       Impact factor: 4.177

8.  Dose escalation or immediate full dose when switching from efavirenz to nevirapine-based highly active antiretroviral therapy in HIV-1-infected individuals?

Authors:  Alan Winston; Anton Pozniak; Nicola Smith; Carl Fletcher; Sundhiya Mandalia; Darmishta Parmar; Sarah Gibbons; David Back; Brian Gazzard; Mark Nelson
Journal:  AIDS       Date:  2004-02-20       Impact factor: 4.177

Review 9.  Switching from suppressive protease inhibitor-based regimens to nevirapine-based regimens: a meta-analysis of randomized controlled trials.

Authors:  J Ena; A Leach; P Nguyen
Journal:  HIV Med       Date:  2008-07-21       Impact factor: 3.180

10.  Efavirenz replacement by immediate full-dose nevirapine is safe in HIV-1-infected patients in Cambodia.

Authors:  D Laureillard; N Prak; M Fernandez; C Ngeth; S Moeung; V Riel; V Chhneang; S Song; C Quillet; C Piketty
Journal:  HIV Med       Date:  2008-06-28       Impact factor: 3.180
View more
  1 in total

1.  Adverse effects of antiretroviral therapy in pregnant women infected with HIV in Brazil from 2000 to 2015: a cohort study.

Authors:  Adriane M Delicio; Giuliane J Lajos; Eliana Amaral; Fabia Lopes; Fernanda Cavichiolli; Isabeli Myioshi; Helaine Milanez
Journal:  BMC Infect Dis       Date:  2018-09-27       Impact factor: 3.090
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.